Settlement Overview
Johnson & Johnson (NYSE: JNJ) announced on Monday that it has reached a proposed agreement to resolve the vast majority of its remaining U.S. ovarian cancer lawsuits linked to its talc products. The company committed to pay a total of $5.5 billion provided that at least 95 % of claimants accept the settlement.
Claims Covered
The settlement is intended to resolve roughly 76,000 ovarian talc claims that are pending in federal multidistrict litigation and related state court proceedings, representing what JNJ described as an efficient conclusion to more than 15 years of litigation.
Legal Context
The agreement follows a recent ruling by the federal multidistrict litigation court that questioned whether plaintiffs could prove that JNJ’s talc products caused any individual claimant’s ovarian cancer. Prior to the court’s order for the plaintiffs to demonstrate why the remaining claims should not be dismissed, the plaintiffs withdrew their specific causation experts in two bellwether cases.
Payment Schedule
Under the terms of the proposed settlement, the first payment will be no more than $3 billion, scheduled for 2027. No additional payments are due before 2028.
Company Position
Johnson & Johnson stated that it remains confident it would have prevailed at trial, but chose the settlement to eliminate the costs and uncertainty associated with prolonged litigation. The company continues to assert that decades of scientific research support the safety of its cosmetic talc, emphasizing that its talc products do not contain asbestos and do not cause cancer.
Product and Liability History
JNJ discontinued its talc‑based Johnson’s Baby Powder globally in 2023. Following the separation of its consumer health business, Kenvue, Johnson & Johnson retained all talc‑related liabilities.